MedTrace Logo

Galectin-3 as a Biomarker in Patients With Chagas Disease

NCT01842854 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2017-11-28

No results posted yet for this study

Summary

The purpose of this study is to analyze the efficacy of Galectin-3 as a biomarker on the Chagas Disease prognosis. This analysis will be done through the correlation between the plasmatic levels of this molecule with functional and laboratory tests.

Conditions

  • Chagas Disease

Sponsors & Collaborators

  • Hospital Sao Rafael

    lead OTHER

Principal Investigators

  • Milena Botelho Pereira Soares, PhD · Hospital São Rafael

  • Ricardo Ribeiro dos Santos, MD, PhD · Hospital São Rafael

  • Ticiana Ferreira Larocca, MD, MSC · Hospital São Rafael

  • Márcia Maria Noya Rabelo, MD, MSC · Hospital São Rafael

  • Luís Cláudio Lemos Correia, MD, PhD · Hospital São Rafael

  • Bruno Solano de Freitas Souza, MD, MSC · Hospital São Rafael

  • Carolina Thé Macedo, MD · Hospital São Rafael

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01842854 on ClinicalTrials.gov